AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer

DSpace/Manakin Repository

AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer

Citable link to this page

 

 
Title: AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer
Author: Kabraji, Sheheryar; Solé, Xavier; Huang, Ying; Bango, Clyde; Bowden, Michaela; Bardia, Aditya; Sgroi, Dennis; Loda, Massimo; Ramaswamy, Sridhar

Note: Order does not necessarily reflect citation order of authors.

Citation: Kabraji, Sheheryar, Xavier Solé, Ying Huang, Clyde Bango, Michaela Bowden, Aditya Bardia, Dennis Sgroi, Massimo Loda, and Sridhar Ramaswamy. 2017. “AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer.” Breast Cancer Research : BCR 19 (1): 88. doi:10.1186/s13058-017-0877-7. http://dx.doi.org/10.1186/s13058-017-0877-7.
Full Text & Related Files:
Abstract: Background: Absence of pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) correlates with poor long-term survival in patients with triple negative breast cancer (TNBC). These incomplete treatment responses are likely determined by mechanisms that enable cancer cells to resist being killed. However, the detailed characterization of a drug-resistant cancer cell state in residual TNBC tissue after NACT has remained elusive. AKT1low quiescent cancer cells (QCCs) are a quiescent, epigenetically plastic, and chemotherapy-resistant subpopulation initially identified in experimental cancer models. Here, we asked whether QCCs exist in primary tumors from patients with TNBC and persist after treatment with NACT. Methods: We obtained pre-treatment biopsy, post-treatment mastectomy, and metastatic specimens from a retrospective cohort of TNBC patients treated with NACT at Massachusetts General Hospital (n = 25). Using quantitative automated immunofluorescence microscopy, QCCs were identified as AKTlow/H3K9me2low/HES1high cancer cells using prespecified immunofluorescence intensity thresholds. QCCs were represented in 2D and 3D digital tumor maps and QCC percentage (QCC-P) and QCC cluster index (QCC-CI) were determined for each sample. Results: We showed that QCCs exist as non-random and heterogeneously distributed clusters within primary breast tumors. In addition, these QCC clusters persist after treatment with multi-agent, multi-cycle, neoadjuvant chemotherapy in both residual primary tumors and nodal and distant metastases in patients with triple negative breast cancer. Conclusions: These first-in-human data potentially qualify AKT1low quiescent cancer cells as a non-genetic cell state that persists after neoadjuvant chemotherapy in triple negative breast cancer patients and warrants further study. Electronic supplementary material The online version of this article (doi:10.1186/s13058-017-0877-7) contains supplementary material, which is available to authorized users.
Published Version: doi:10.1186/s13058-017-0877-7
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540189/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:34375224
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters